Chemotherapy-Induced Cognitive Impairment

tibbi onkoloji ozel 13-4 kapak

Özge DOKUZLARa, Pınar SOYSALb, Ahmet Turan IŞIKc

aDokuz Eylül Üniversitesi Tıp Fakültesi, Geriatri BD, İzmir, TÜRKİYE
bBezmialem Vakıf Üniversitesi Tıp Fakültesi, Geriatri BD, İstanbul, TÜRKİYE
cDokuz Eylül ÜniversitesiTıp Fakültesi, Geriatri BD, Yaşlanan Beyin ve Demans Ünitesi, İzmir, TÜRKİYE

ABSTRACT
Today, with the advances in cancer treatments, survival times have increased, which has made treatment side effects more important. Cancer-related cognitive insufficiency is one of the problems that may arise during or after treatment. Especially, memory, attention, executive functions and negative effects of psychomotor speed have been shown. It is important for both the patient and the caregivers to affect the quality of life and the increase in health expenditures. Many factors are responsible for the pathogenesis. Although there is currently no specific treatment, there are agents that show benefit. Routine screening seems to be important for early diagnosis and treatment of patients.
Keywords: Cognition disorders; drug therapy; medical oncology; neoplasms; aged

Referanslar

  1. Işık AT, Bozoğlu E. Bilişsel (Kognitif) Yaslanma. In: I ̧ şık AT, Tanrıdağ O, editör. Geriatri Pratiğinde Demans Sendromu. 1. Baskı. İstanbul: Som Kitap; 2009. p.19-30.
  2. Işık AT. Yaşlanma Sürecinde Beyin ve Kognisyon. In: Işık AT, editör. Her Yönüyle Alzheimer Hastalığı. 1. Baskı. İstanbul: Som Kitap; 2012. p.105-122.
  3. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102-13. [Crossref]  [PubMed]  [PMC]
  4. Pendergrass JC, Targum SD, Harrison JE. Cognitive impairment associated with cancer: A brief review. Innov Clin Neurosci. 2018;15 (1-2):36-44.
  5. Craig CD, Monk BJ, Farley JH, Chase DM. Cognitive impairment in gynecologic cancers: A systematic review of current approaches to diagnosis and treatment. Support Care Cancer. 2014;22:279-87. [Crossref]  [PubMed]
  6. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancerand chemotherapy-related cognitive dysfunction: Current status. Semin Oncol. 2011;38 (3):431-8. [Crossref]  [PubMed]  [PMC]
  7. Vega JN, Dumas J, Newhouse PA. Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults. Am J Geriatr Psychiatry. 2017;25(12):1415-26. [Crossref]  [PubMed]  [PMC]
  8. McAllister TW, Ahles TA, Saykin AJ, Ferguson RJ, McDonald BC, Lewis LD, et al. Cognitive effects of cytotoxic cancer chemo- therapy: Predisposing risk factors and potential treatments. Curr Psychiatry Rep. 2004;6 (5):364- 71. [Crossref]  [PubMed]
  9. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12:267-75. [Crossref]  [PubMed]
  10. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192-201. [Crossref]  [PubMed]  [PMC]
  11. Horowitz TS, Suls J, Treviño M. A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment. Trends Neurosci. 2018;41(8):493-6. [Crossref]  [PubMed]
  12. Işık AT, Soysal P. Kognitif Yıkımlar: Geri Dönüşümlü. Turkiye Klin J Geriatr-Special Top. 2015;1(2):1-6.
  13. Işık AT, Babacan Yıldız G. Nörokognitif Değerlendirme. In: Soysal P, Işık AT, editör. Geriatri Pratiğinde Ölçekler. 1. Baskı. İstanbul: İstanbul Tıp; 2017. p.53-74.
  14. Loh KP, Janelsins MC, Mohile SG, Holmes HM, Hsu T, Inouye SK, et al. Chemotherapyrelated cognitive impairment in older patients with cancer. J Geriatr Oncol. 2016;7(4):270- 80. [Crossref]  [PubMed]  [PMC]
  15. Myers JS. Neuropsychologic testing for chemotherapy-related cognitive impairment. Adv Exp Med Biol. 2010;678:55-69. [Crossref]  [PubMed]
  16. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703-8. [Crossref]  [PubMed]
  17. Ren X, St. Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemo- therapy induced cognitive impairment. Pharmacol Res. 2017;117:267-73. [Crossref]  [PubMed]
  18. Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer. 2013;21(4): 1185-92. [Crossref]  [PubMed]  [PMC]
  19. Parsons M, Dietrich R. Assessment and management of cognitive changes in patients with cancer. Cancer. 2019;Epub ahead. [Crossref]